Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CCCC NYSEARCA:IWM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCCCCC4 Therapeutics$2.61+0.4%$2.01$1.09▼$7.22$185.04M2.971.64 million shs610,102 shsIWMiShares Russell 2000 ETF$225.97+0.2%$220.19$171.73▼$244.98$64.63B1.1532.91 million shs24.47 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCCCCC4 Therapeutics-5.80%+11.59%+14.54%+89.78%-57.02%IWMiShares Russell 2000 ETF-0.35%-2.51%+1.80%+10.93%+5.98%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCCCCC4 Therapeutics1.2405 of 5 stars3.22.00.00.00.01.70.0IWMiShares Russell 2000 ETFN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCCCCC4 Therapeutics 2.33Hold$8.00206.51% UpsideIWMiShares Russell 2000 ETF 2.75Moderate Buy$225.97N/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCCCCC4 Therapeutics$35.58M5.22N/AN/A$2.45 per share1.07IWMiShares Russell 2000 ETFN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCCCCC4 Therapeutics-$105.32M-$1.58N/AN/AN/A-325.88%-53.91%-33.26%10/30/2025 (Estimated)IWMiShares Russell 2000 ETFN/AN/A17.69∞N/AN/AN/AN/AN/ALatest CCCC and IWM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025CCCCC4 Therapeutics-$0.38-$0.37+$0.01-$0.37$5.24 million$6.46 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCCCCC4 TherapeuticsN/AN/AN/AN/AN/AIWMiShares Russell 2000 ETF$2.481.10%N/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCCCCC4 TherapeuticsN/A5.065.06IWMiShares Russell 2000 ETFN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCCCCC4 Therapeutics78.81%IWMiShares Russell 2000 ETFN/AInsider OwnershipCompanyInsider OwnershipCCCCC4 Therapeutics8.73%IWMiShares Russell 2000 ETFN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCCCCC4 Therapeutics15071.17 million64.96 millionOptionableIWMiShares Russell 2000 ETFN/A286.00 millionN/ANot OptionableCCCC and IWM HeadlinesRecent News About These CompaniesAre Small-Cap ETFs Finally Ready to Shine?August 19 at 12:01 PM | zacks.comLouis Moore Bacon's Strategic Moves: iShares Russell 2000 ETF Sees Significant ReductionAugust 15, 2025 | gurufocus.comZacks Investment Ideas feature highlights: IWM, ETHA, IBIT and XXRPAugust 14, 2025 | finance.yahoo.com4 Factors That Could Give Small-Cap ETFs a Boost AheadAugust 14, 2025 | zacks.comThis ETF’s Rally Sparks Hope: Are Small-Cap Stocks Ready to Rebound?August 13, 2025 | 247wallst.comThis ETF's Rally Sparks Hope: Are Small-Cap Stocks Ready to Rebound?August 13, 2025 | 247wallst.comSmall-Cap ETFs Outperform on Inflation DataAugust 13, 2025 | zacks.comDo Lower Rates Suggest Small Cap Stocks are in Favor?August 13, 2025 | zacks.com5 ETFs to Benefit if Fed Cuts Rate in SeptemberAugust 11, 2025 | zacks.comDow, S&P 500 Futures Climb Ahead Of McDonald’s, Disney Earnings — Strategist Says Tariff Effect Biggest Risk As Market Enters Seasonally Weak PeriodAugust 6, 2025 | msn.com3 Reasons the Market Can Rally, 2 Ways to Diversify If It Doesn't (IWM)...August 5, 2025 | marketbeat.comAll the pain for none of the discount: Why small caps are so toxic right nowJuly 31, 2025 | msn.com3 Reasons To Favor IJR Over IWM In Case High Rates PersistJuly 31, 2025 | seekingalpha.comAre Small Caps Finally Ready to Take the Leap?July 25, 2025 | zacks.comRussell 2000 (IWM) and Semiconductors (SMH): Concerning Price Pattern?July 20, 2025 | seeitmarket.comSNvidia, Google Most Bought US Stocks By Indians In April-JuneJuly 17, 2025 | msn.comShould iShares Russell 2000 ETF (IWM) Be on Your Investing Radar?July 17, 2025 | zacks.com2 Income Engines Fuelling Weekly CheckJuly 16, 2025 | seekingalpha.comKey Stock Market Indices & ETFs: Minding July Trading RangesJuly 15, 2025 | seeitmarket.comSTired of Trading Large-Caps? Downsize With These ETFsJuly 9, 2025 | etftrends.comEUnusual Options Activity: Is the iShares Russell 2000 ETF the Best Way to Play Small Caps?July 3, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCCCC and IWM Company DescriptionsC4 Therapeutics NASDAQ:CCCC$2.61 +0.01 (+0.38%) Closing price 04:00 PM EasternExtended Trading$2.59 -0.02 (-0.77%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.iShares Russell 2000 ETF NYSEARCA:IWM$225.97 +0.56 (+0.25%) Closing price 04:10 PM EasternExtended Trading$226.58 +0.61 (+0.27%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iShares Russell 2000 ETF (the Fund) is an exchange-traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Russell 2000 Index (the Index). The Index is a float-adjusted capitalization weighted index that measures the performance of the small-capitalization sector of the United States equity market and includes securities issued by the approximately 2,000 smallest issuers in the Russell 3000 Index. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. The Index is a subset of the Russell 3000 Index, and serves as the underlying index for the Russell 2000 Growth and Value Index series. Component companies are adjusted for available float and must meet objective criteria for inclusion to the Index. The Fund's investment adviser is BlackRock Fund Advisors (BFA). More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Robotics Stocks at the Heart of the Robotics Revolution Analog Devices and an AI-Driven Semiconductor Supercycle Palantir is Selling Off, BigBear.ai Could Be Your Hedge ASML Has Entered Buy Territory, But Only For Patient Investors Lowe’s Builds Value for Investors: Still a Good Buy in 2025 Target: Missing the Mark in 2025—Downtrend May Continue Toll Brothers: A Great Buy and Hold Stock With Risks in 2025 Amazon Stock Sets Up for Breakout After Bullish Crossover Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access